Clinical trial
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
NCT02715284 is registered in ClinicalTrials.gov with Tesaro, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
- Lead sponsor
- Tesaro, Inc.
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- March 7, 2016
- Completion date
- April 14, 2028
- Enrollment
- 729 (actual)
- Sites
- 128
Conditions
As the registry lists them; a condition with its own page is linked.